We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA: International Agreement Will Not Result in Additional Burdens on Personalized Medicine
FDA: International Agreement Will Not Result in Additional Burdens on Personalized Medicine
April 28, 2006
An international effort between the U.S., the European Union and Japan to standardize industry submission and agency review of genomic data will move personalized medicine forward without increasing regulatory burdens, a high-ranking FDA official says.